<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="637">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385526</url>
  </required_header>
  <id_info>
    <org_study_id>E-40</org_study_id>
    <nct_id>NCT02385526</nct_id>
  </id_info>
  <brief_title>Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>ASCEND: Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability
      and clinical outcomes study to determine the number of patients achieving their final
      assigned VNS Therapy dose settings in patients with drug-resistant epilepsy who are being
      treated with adjunctive VNS Therapy using new titration protocols.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability
      and clinical outcomes study is designed to determine which VNS Therapy titration paradigm
      allows more patients to achieve a therapeutic dose within a specified time frame.
      Additionally, the study will collect data on the acute tolerability and clinical outcomes
      for patients with drug-resistant epilepsy treated with adjunctive VNS Therapy employing
      three different titration paradigms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percent patients reaching the defined therapeutic dose</measure>
    <time_frame>12 weeks post implant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of the proportion (percent) of patients in each VNS Therapy titration group reaching the defined therapeutic dose within clinically defined titration time-frame.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epilepsy</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Vagus Nerve Stimulation Therapy Standard Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Vagus Nerve Stimulation Therapy Alternate Titration 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Vagus Nerve Stimulation Therapy Alternate Titration 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagus Nerve Stimulation Therapy</intervention_name>
    <description>Stimulation of the left tenth cranial nerve via VNS Therapy</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>VNS Therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study shall include adults and adolescents over 12 years of age with partial onset
        seizures that are refractory to antiepileptic medications and eligible for VNS Therapy
        indicated for use as an adjunctive therapy in reducing the frequency of seizures.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must agree to be treated with VNS Therapy. The decision to treat with VNS
             Therapy must have been made independent of and prior to participation in the study.

          2. Patients must be 12 years or older and have partial onset seizures or must follow the
             indication for use statement for VNS Therapy.

          3. Patient and/or caregiver must be able and willing to give accurate side effect
             reports, global impressions data and complete study instruments with minimal
             assistance throughout the study.

          4. Patient or legal guardian understands study procedures and voluntarily signs an
             informed consent and Health Insurance Portability and Accountability Act (HIPAA)
             authorization in accordance with institutional policies. In the event the patient is
             under the age of 18, the patient will also be required to sign an assent affirming
             agreement to participate in research according to local IRB requirements.

          5. Patient must be taking at least 1 anti-epileptic drug treatment

        Exclusion Criteria:

          1. Patient currently uses, or is expected to use during the study, short-wave diathermy,
             microwave diathermy, or therapeutic ultrasound diathermy.

          2. Patient is expected to require MRI using a body coil for transmission of RF during
             the clinical study.

          3. Patient has a progressive neurological condition (e.g. brain tumor etc.).

          4. In the investigator's opinion, the patient or legal guardian is unable to comply with
             the frequency of clinic visits during the study.

          5. Patient is currently using an investigational device or pharmacologic medication not
             approved by the FDA.

          6. Patient was previously implanted with VNS Therapy.

          7. In the investigator's opinion, the patient is considered a suicide risk or is
             otherwise not a good candidate for this study.

          8. Patient/Caregiver is unable to complete the required study follow-up visits and
             assessments.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Begnaud</last_name>
    <role>Study Director</role>
    <affiliation>Cyberonics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Begnaud</last_name>
    <phone>281-228-7263</phone>
    <email>jason.begnaud@cyberonics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheba Baroya</last_name>
      <phone>909-558-2037</phone>
      <email>SBaroya@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Tavis Losey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Oviedo</last_name>
      <phone>323-445-9873</phone>
      <email>sandra.oviedo@health.usc.edu</email>
    </contact>
    <investigator>
      <last_name>George Nune, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara McTigue</last_name>
      <phone>813-259-0826</phone>
      <email>tmctigue@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Selim Benbadis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanee Newman</last_name>
      <phone>404-778-3444</phone>
      <email>mnewman2@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Sandra Helmers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Clark</last_name>
      <phone>859-313-4210</phone>
      <email>bgepilepsy@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Toufic Fakhoury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Research Institue</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Thompson</last_name>
      <phone>417-820-9123</phone>
      <email>linda.thompson@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Roger Oghlakian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Klingensmith</last_name>
      <phone>412-864-2401</phone>
      <email>klingensmithk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Anto Bagic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Castillo</last_name>
      <phone>254-724-7727</phone>
      <email>rccastillo@sw.org</email>
    </contact>
    <investigator>
      <last_name>Batool Kirmani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Larrinaga</last_name>
      <phone>801-585-9266</phone>
      <email>stacey.larrinaga@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Pegah Afra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>October 2, 2015</lastchanged_date>
  <firstreceived_date>March 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vagus Nerve Stimulation</keyword>
  <keyword>ASCEND</keyword>
  <keyword>VNS Titration to Improve Tolerance and Accelerate Adaptation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
